Jendle, J. http://orcid.org/0000-0003-1025-1682
Buompensiere, M. I.
Holm, A. L.
de Portu, S.
Malkin, S. J. P.
Cohen, O.
Article History
Received: 9 March 2022
Accepted: 9 March 2022
First Online: 11 April 2022
Declarations
:
: Funding for this letter was provided by Medtronic International Trading Sàrl.
: Johan Jendle has received speaker’s and/or consultant fees from Abbott, Ascensia, AstraZeneca, Boehringer Ingelheim, Eli-Lilly, Medtronic, Nordic Infucare, Novo Nordisk and Sanofi. Maria Ida Buompensiere, Simona de Portu and Ohad Cohen are employees of Medtronic International Trading Sàrl. Astrid Ledgaard Holm is an employee of Medtronic Denmark. Samuel Joseph Paul Malkin is an employee of Ossian Health Economics and Communications GmbH, which received consulting fees to support preparation of the cost-effectiveness manuscript. Editorial support for the response letter was provided by Covalence Research Ltd, which was funded by Medtronic International Trading Sàrl.
: All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.
: All authors contributed to the response and have approved the final version. Editorial support was provided by Covalence Research Ltd; editorial support was funded by Medtronic International Trading Sàrl.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.